NeurAxis to Participate in the Lytham Partners Spring 2025 Investor Conference on May 29, 2025

Rhea-AI Summary

NeurAxis (NYSE American: NRXS), a medical technology company focused on neuromodulation therapies for chronic conditions in children and adults, has announced its participation in the upcoming Lytham Partners Spring 2025 Investor Conference. The virtual event will take place on May 29, 2025.

The company will deliver a webcast presentation at 9:30 a.m. ET and conduct one-on-one meetings with investors throughout the event. Interested parties can access the webcast through the conference website or directly via the provided link, with replay options available after the event.

CARMEL, Ind., May 27, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, will participate in a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Spring 2025 Investor Conference, taking place virtually on Thursday, May 29, 2025.

Company Webcast

The webcast presentation will take place at 9:30 a.m. ET on Thursday, May 29, 2025. The webcast can be accessed by visiting the conference home page at https://lythampartners.com/spring2025/ or directly at https://app.webinar.net/qdroK7R5BZy. The webcast will also be available for replay following the event.

1x1 Meetings

Management will be participating in virtual one-on-one meetings throughout thae event. To arrange a meeting with management, please contact Lytham Partners at 1x1@lythampartners.com or register for the event at https://lythampartners.com/spring2025invreg/.

About NeurAxis, Inc.

NeurAxis, Inc., is a medical technology company focused on neuromodulation therapies to address chronic and debilitating conditions in children and adults. NeurAxis is dedicated to advancing science and leveraging evidence-based medicine to drive adoption of its IB-Stim™ therapy, which is its proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology, by the medical, scientific, and patient communities. IB-Stim™ is FDA cleared for functional abdominal pain associated with irritable bowel syndrome (IBS) in adolescents 8-21 years old. Additional clinical trials of PENFS in multiple pediatric and adult conditions with large unmet healthcare needs are underway. For more information, please visit http://neuraxis.com.

Forward-Looking Statements

Certain statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements. Forward-looking statements are based on management’s current assumptions and expectations of future events and trends, which affect or may affect the Company’s business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. There are a number of important factors that could cause actual results, developments, business decisions or other events to differ materially from those contemplated by the forward-looking statements in this press release. These factors include, among other things, the conditions in the U.S. and global economy, the trading price and volatility of the Company’s stock, public health issues or other events, the Company’s compliance with applicable laws, the results of the Company’s clinical trials and perceptions thereof, the results of submissions to the FDA, the results of the shareholder vote to enable the issuance of the Preferred Stock, and factors described in the Risk Factors section of NeurAxis’s public filings with the Securities and Exchange Commission (SEC). Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of the date of this press release and, except to the extent required by applicable law, the Company undertakes no obligation to update or revise these statements, whether as a result of any new information, future events and developments or otherwise.

Contacts:

Company
NeurAxis, Inc.
info@neuraxis.com

Investor Relations

Ben Shamsian
Lytham Partners
646-829-9701
shamsian@lythampartners.com

FAQ

When is NeurAxis (NRXS) presenting at the Lytham Partners Spring 2025 Conference?

NeurAxis (NRXS) will present at 9:30 a.m. ET on Thursday, May 29, 2025, during the virtual Lytham Partners Spring 2025 Investor Conference.

How can investors access the NeurAxis (NRXS) presentation at the Lytham Conference?

Investors can access the webcast through the conference website at lythampartners.com/spring2025/ or directly at app.webinar.net/qdroK7R5BZy. A replay will be available after the event.

How can investors arrange one-on-one meetings with NeurAxis (NRXS) management?

Investors can arrange one-on-one meetings by contacting Lytham Partners at 1x1@lythampartners.com or by registering at lythampartners.com/spring2025invreg/.

What type of medical technology does NeurAxis (NRXS) develop?

NeurAxis develops and commercializes neuromodulation therapies that address chronic and debilitating conditions in both children and adults.